Why Crizotinib Still Matters in the Fast-Changing World of Precision Oncology
Crizotinib remains a pivotal therapy in precision oncology, especially for patients with ALK-positive or ROS1-positive non-small cell lung cancer. What makes it especially relevant today is not just its established efficacy, but how it continues to shape treatment sequencing discussions as clinicians weigh durability of response, resistance patterns, and real-world patient outcomes. In a market …
Why Crizotinib Still Matters in the Fast-Changing World of Precision Oncology Read More »